Lost Covid revenues replaced w/anti-cancer; $25M deal signedNo wonder the board is flooded with new posters desperately bashing. Who spends their day bashing a stock they don't own?
Paid bashers working to facilitate a cheap hostile takeover, that's who...
I own this, (just bought a whack of fresh shares last week) and I can rarely be bothered to post even once a week.
But, of course, that's because I'm a real investor, lol.
Same goes for GGY, who are accepting warrants in a bid to get in on the action. (All around, this deal is pretty brilliant for shareholders, whose interests Tripp is protecting, to the chagrin of market sharks and profiteers.)
The company's revenues were down far less than I expected in the summer, when most people aren't thinking of cancer testing. Interest is clearly growing, and Aristotle's successes, (especially in the face of Grail's failures) make this the dark horse to watch.
Buy cheap now, and hold for tomorrow.
Longs will reap the very real rewards.
GLTA!